Bain Capital
Company
Bain Capital develops 4 assets, the furthest approved (canagliflozin in albuminuria). Mostly small molecule and antibody acting on Insulin/IGF-1 signalling, lipid and ceramide metabolism and glycolysis.
- 4
- Assets
- Furthest stage
- Approved
- 20
- Trials
- 4
- Signals
Pipeline
4Sodium-glucose cotransporter 2 (SGLT2) inhibitor that lowers blood glucose by increasing urinary glucose excretion.
Approved, Small molecule, AMPK signalling, Insulin/IGF-1 signalling, albuminuria, cardiovascular death
Binds CD19 and depletes B cells, reducing pathogenic autoantibody production.
Approved, Antibody, Inflammation, MS4A1, generalized myasthenia gravis, membranous glomerulonephritis (Phase 3)
Naturally occurring bile acid that modulates bile acid pool, reduces apoptosis, and protects hepatocytes.
Approved, Small molecule, Oxidative stress and ROS signalling, Apoptosis, primary biliary cholangitis, systemic disease
1 more asset
Full company profiles: pipeline, trials, funding and people.
Subsidiaries
14 assets, 20 trials
In the full profile
- Evidence behind the mechanisms12
- Trials22
- Signals7
- Similar companies6